Vancouver, British Columbia– Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines used in oncology, rare disease and infectious disease, today announced that Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada on Wednesday, May 1, 2019 at 11:00 am ET.
“We are excited about our strong commercial momentum and continued rapid adoption of PNI’s platform,” said Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, “In 2019, we look forward to launches of innovative product and continuing to work with our clients to develop transformative medicines.“
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
About the Bloom Burton & Co. Healthcare Investor Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.